Loading...

LSTA LISATA THERAPEUTICS INC Disposals and divestitures 8-K Filing

LST

LST

LISATA THERAPEUTICS INC

(LSTA)

2026 8-K

Tender Offer Extension

Merger Agreement Announced

Acquisition Update

Collaboration Termination

Acquisition Announcement

Financial Results Report

Investor Presentation Update

New License Agreement

Financial Statements

Product Expansion

Regulation FD Disclosure

Compensatory Arrangements

Financial Statements

Financial Results

Trial Data Release

Collaboration Agreement

Q3 Financial Results

Q2 Financial Results

Annual Meeting of Stockholders

Earnings Reports

Appointment of James Nisco

Financial Results and Prese...

Earnings Reports

Earnings Reports

Termination of Employment

Financial Update

External Links:

On January 23, 2026, Lisata Therapeutics, Inc. terminated its licensing agreement with Qilu Pharmaceutical Co., Ltd., which could have provided up to $200 million in milestone payments and royalties of 10% to 15% from sales.

AI Assistant

LISATA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.